Paritaprevir (ABT-450) dihydrate is a potent, orally active and antiviralnon-structural protein 3/4A (NS3/4A) proteaseinhibitor with EC₅₀s of 1 and 0.21 nM againstHCV1a and 1b, respectively. Paritaprevir dihydrate is also aSARS-CoV3CL^proinhibitor with an IC₅₀of 1.31 μM. Paritaprevir dihydrate is metabolized primarily bycytochrome P450(CYP) 3A. The plasma concentration and half-life of Paritaprevir dihydrate can be enhanced byRitonavir(a CYP450 inhibitor)^[1][2][3][4].

EC₅₀: 1 nM (HCV 1a), 0.21 nM (HCV 1b)^[1]
IC₅₀: 1.31 μM (SARS-CoV 3CL^pro)^[3]

Paritaprevir hasin vitroantiviral activity against HCV GT1-4 and GT6 (EC₅₀range, 0.09 to 19 nM), with an EC₅₀of 0.09 nM against GT4a^[2].

The combination of Paritaprevir,Ritonavir,Ombitasvir(an NS5A protein inhibitor), andDasabuvir(an NS5B non-nucleoside polymerase inhibitor) with or without RBV has been approved to treat HCV genotype 1 infections^[1][4].
The acute toxicity of Paritaprevir is considered to be low. Single oral doses of ≤600 mg/kg in rats and ≤100 mg/kg in dogs produces no mortality and were well tolerated. However, since Paritaprevir is administered without ritonavir as a PK enhancer, the exposures are low, especially in male rats (rat 600 mg/kg, males: C_max1.82 μg/mL, AUC_0-248.89 μg·h/mL; dog 100 mg/kg, mean: C_max61.3 μg/mL, AUC_0-24285 μg·h/mL).

801.91

C₄₀H₄₇N₇O₉S

1456607-71-8

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.